Market Research Logo

Global Bronchitis Drugs Market 2018-2022

Global Bronchitis Drugs Market 2018-2022

About this market

For bettering the public understanding of the disease, many government as well as non-government agencies are taking initiatives to improve public awareness of bronchitis. Many organizations suggest not to treat acute bronchitis with antibiotics, as such drugs are not indicated for diseases like acute bronchitis. Moreover, there are a few not-for-profit foundations on asthma and other respiratory illnesses, such as the Asthma Foundation, which offer support to patients. Asthma Foundation focuses on increasing the awareness of respiratory illnesses, funds research for better treatments, and provides education on best practices. Such initiatives for generating awareness of bronchitis among patients and physicians will result in better diagnosis of bronchitis and help in the global market's growth. Technavio’s analysts have predicted that the bronchitis drugs market will register a CAGR of close to 4% by 2022.

Market Overview

Strong pipeline

Bronchitis treatment has a strong pipeline due to the extensive R&D in this field. Currently, the bronchitis treatment pipeline has around 6 trials in phase I, phase II, and phase III, in which 3 are in phase III. There are a few promising molecules in the pipeline for indications such as acute and chronic bronchitis.

High economics burden of bronchitis

Incomplete or inaccurate diagnosing of chronic bronchitis can have a substantial impact on healthcare costs, resulting in a higher economic burden for people with the disease.

For the detailed list of factors that will drive and challenge the growth of the bronchitis drugs market during the 2018-2022, view our report.

Competitive Landscape

The bronchitis drugs market is moderately fragmented with the presence of several bronchitis drug manufacturers. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


  • Executive summary
  • Scope of the report
  • Research methodology
  • Market landscape
    • Market ecosystem
      • Table Parent market
      • Table Global respiratory drugs market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Pipeline analysis
    • Bronchitis pipeline
      • Table Pipeline drugs for bronchitis 2017-2018
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global bronchitis drugs market - Market size and forecast 2017-2022 ($ bn)
      • Table Global bronchitis drugs market - Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2017
  • Segmentation by drug type
    • Antibiotics
    • Anti-inflammatory drugs
    • Bronchodilators
      • Table LABAs with their respective time of onset of action and duration of action
    • Mucolytics
  • Market segmentation by application
    • Segmentation by application
      • Table Global bronchitis drugs market by application - Market share 2017-2022 (%)
    • Comparison by application
      • Table Comparison by application
    • Acute bronchitis - Market size and forecast 2017- 2022
      • Table Acute bronchitis - Market size and forecast 2017-2022 ($ bn)
      • Table Acute bronchitis - Year-over-year growth 2018-2022 (%)
    • Chronic bronchitis - Market size and forecast 2017-2022
      • Table US FDA-approved LABAs and LAMAs FDC
      • Table Chronic bronchitis - Market size and forecast 2017-2022 ($ bn)
      • Table Chronic bronchitis - Year-over-year growth 2018-2022 (%)
    • Market opportunity by application
      • Table Market opportunity by application
  • Customer Landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global bronchitis drugs market by geography - Market share 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • EMEA - Market size and forecast 2017-2022
      • Table EMEA - Market size and forecast 2017-2022 ($ bn)
      • Table EMEA - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in EMEA
    • Americas - Market size and forecast 2017-2022
      • Table Americas - Market size and forecast 2017-2022 ($ bn)
      • Table Americas - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in Americas
    • APAC - Market size and forecast 2017-2022
      • Table APAC - Market size and forecast 2017-2022 ($ bn)
      • Table APAC - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Late-stage pipeline drugs for bronchitis 2017-2018
    • Market challenges
  • Market trends
    • High use of antibiotics for bronchitis treatment
    • Use of off-label drugs for bronchitis
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AstraZeneca
      • Table AstraZeneca: An overview
      • Table AstraZeneca - Business segments
      • Table AstraZeneca - Organizational developments
      • Table AstraZeneca - Geographic focus
      • Table AstraZeneca - Key offerings
    • GlaxoSmithKline
      • Table GlaxoSmithKline: An overview
      • Table GlaxoSmithKline - Business segments
      • Table GlaxoSmithKline - Organizational developments
      • Table GlaxoSmithKline - Geographic focus
      • Table GlaxoSmithKline - Segment focus
      • Table GlaxoSmithKline - Key offerings
    • Novartis
      • Table Novartis: An overview
      • Table Novartis - Business segments
      • Table Novartis - Organizational developments
      • Table Novartis - Geographic focus
      • Table Novartis - Segment focus
      • Table Novartis - Key offerings
    • Sanofi
      • Table Sanofi: An overview
      • Table Sanofi - Business segments
      • Table Sanofi - Organizational developments
      • Table Sanofi - Geographic focus
      • Table Sanofi - Segment focus
      • Table Sanofi- Key offerings
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report